KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Receivables (2016 - 2025)

Opko Health's Receivables history spans 16 years, with the latest figure at $111.7 million for Q4 2025.

  • For Q4 2025, Receivables fell 21.88% year-over-year to $111.7 million; the TTM value through Dec 2025 reached $111.7 million, down 21.88%, while the annual FY2025 figure was $111.7 million, 21.88% down from the prior year.
  • Receivables reached $111.7 million in Q4 2025 per OPK's latest filing, down from $119.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $320.5 million in Q1 2021 to a low of $492000.0 in Q2 2021.
  • Average Receivables over 5 years is $128.4 million, with a median of $122.5 million recorded in 2022.
  • Peak YoY movement for Receivables: plummeted 99.77% in 2021, then skyrocketed 32100.2% in 2022.
  • A 5-year view of Receivables shows it stood at $259.6 million in 2021, then tumbled by 49.36% to $131.5 million in 2022, then tumbled by 98.01% to $2.6 million in 2023, then soared by 5380.23% to $143.0 million in 2024, then fell by 21.88% to $111.7 million in 2025.
  • Per Business Quant, the three most recent readings for OPK's Receivables are $111.7 million (Q4 2025), $119.2 million (Q3 2025), and $125.4 million (Q2 2025).